Clinical Trial Detail

NCT ID NCT02063724
Title HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant)
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Her2-receptor positive breast cancer

Therapies

HER2-pulsed DC1 vaccine

Age Groups: adult senior

Additional content available in CKB BOOST